

In the Sequence Listing:

Please insert the attached paper copy of the Sequence Listing as new pages 1-132 in the above captioned application. A computer readable form copy (CRF) accompanies this response.

**AMENDMENT**

In the claims:

---

146. (Amended) A method for making a peptide which comprises an HLA-A2.1 restricted T cell binding motif, said binding motif consisting of 9-10 amino acid residues, and wherein said peptide binds an HLA-A2.1 molecule, said method comprising the steps of

- (a) providing an amino acid sequence of an antigen of interest;
- (b) identifying within said sequence a subsequence consisting of 9-10 amino acid residues which subsequence has a first amino acid anchor at position 2 of said subsequence selected from the group consisting of L, M, I, V, A and T and a second amino acid anchor residue at the C-terminus of said subsequence selected from the group consisting of A and M (SEQ ID NOS: 350-351); or

which subsequence has a first amino acid anchor at position 2 of said subsequence selected from the group consisting of I, V, A and T and a second amino acid anchor residue at the C-terminus of said subsequence selected from the group consisting of L, V, I, A and M (SEQ ID NOS 352-353);

- (c) identifying a fragment of said antigen which contains a subsequence identified in step (b); and

- (d) preparing a peptide which contains said fragment.

147. (Amended) The method of claim 146, wherein said subsequence consists of 9 amino acid residues and wherein

position 1 of said subsequence is not an amino acid selected from the group consisting of D, E and P (SEQ ID NOS: 354-355), or

position 3 or 7 of said subsequence is not an amino acid selected from the group consisting of D, E, R, K and H (SEQ ID NOS: 356-359), or

position 6 of said subsequence is not an amino acid selected from the group consisting of R, K and H (SEQ ID NOS: 360-361).

148. (Amended) The method of claim 147, wherein  
position 1, 3 or 5 of said subsequence is selected from the group consisting of Y, F and W (SEQ ID NOS: 362-381), or  
position 4 of said subsequence is selected from the group consisting of S, T and C (SEQ ID NOS: 382-389), or  
position 7 of said subsequence is A (SEQ ID NO: 390-395).

149. (Amended) The method of claim 146, wherein the subsequence consists of 10 amino acid residues, and wherein  
position 1 of said subsequence is not an amino acid selected from the group consisting of D, E and P (SEQ ID NOS: 396-397), or  
position 3 of said subsequence is not an amino acid selected from the group consisting of D and E (SEQ ID NOS: 398-399), or  
position 4 of said subsequence is not an amino acid selected from the group consisting of R, K, H and A (SEQ ID NOS: 400-401), or  
position 5 of said subsequence is not P (SEQ ID NOS: 402-403), or  
position 7 of said subsequence is not an amino acid selected from the group consisting of R, K and H (SEQ ID NOS: 404-405), or  
position 8 of said subsequence is not an amino acid selected from the group consisting of D, E, R, K and H (SEQ ID NOS: 406-407), or  
position 9 of said subsequence is not an amino acid selected from the group consisting of R, K and H (SEQ ID NOS: 408-409).

150. (Amended) The method of claim 149, wherein  
position 1 of said subsequence is selected from the group consisting of A, Y, F and W (SEQ ID NOS: 410-423), or

position 3 of said subsequence is selected from the group consisting of L, V, I and M (SEQ ID NOS: 424-435), or

position 4 of said subsequence is G (SEQ ID NOS: 436-447), or

*H<sup>1</sup> covered*  
position 8 of said subsequence is selected from the group consisting of Y, F, W, L, V, I and M (SEQ ID NOS: 448-459).

---

154. (Amended) A method to design a peptide which consists of less than 15 amino acids and which peptide comprises a subsequence consisting of 9-10 amino acids which binds an HLA-A2.1 molecule which method comprises

- H<sup>1</sup>*
- (a) providing an amino acid sequence of an antigen of interest;
  - (b) identifying within said sequence an amino acid subsequence consisting of 9-10 amino acid residues which subsequence has a first amino acid anchor at position 2 of said subsequence selected from the group consisting of L, M, I, V, A and T and a second amino acid anchor at the C-terminus of said subsequence selected from the group consisting of A and M (SEQ ID NOS: 350-351); or

which subsequence has a first amino acid anchor at position 2 of said subsequence selected from the group consisting of I, V, A and T and a second amino acid anchor at the C-terminus of said subsequence selected from the group consisting of L, V, I, A and M (SEQ ID NOS: 352-353);

- (c) identifying a fragment of said antigen which contains a subsequence identified in step (b); and
  - (d) designing a peptide which comprises said fragment.
- 

156. (Amended) The method of claim 154, wherein said subsequence consists of 9 amino acid residues and wherein

*H<sup>1</sup>*  
position 1 of said subsequence is not an amino acid selected from the group consisting of D, E and P (SEQ ID NOS: 354-355), or

position 3 or 7 of said subsequence is not an amino acid selected from the group consisting of D, E, R, K and H (SEQ ID NOS: 356-359), or

position 6 of said subsequence is not an amino acid selected from the group consisting of R, K and H (SEQ ID NOS: 360-361).

157. (Amended) The method of claim 156, wherein

position 1, 3 or 5 of said subsequence is selected from the group consisting of Y, F and W

(SEQ ID NOS: 362-381), or

position 4 of said subsequence is selected from the group consisting of S, T and C (SEQ ID NOS: 382-389), or

position 7 of said subsequence is A (SEQ ID NOS: 390-395).

413 158. (Amended) The method of claim 154, wherein the subsequence consists of 10 amino acid residues, and wherein

position 1 of said subsequence is not an amino acid selected from the group consisting of D, E and P (SEQ ID NOS: 396-397), or

position 3 of said subsequence is not an amino acid selected from the group consisting of D and E (SEQ ID NOS: 398-399), or

position 4 of said subsequence is not an amino acid selected from the group consisting of R, K, H and A (SEQ ID NOS: 400-401), or

position 5 of said subsequence is not P (SEQ ID NOS: 402-403), or

position 7 of said subsequence is not an amino acid selected from the group consisting of R, K and H (SEQ ID NOS: 404-405), or

position 8 of said subsequence is not an amino acid selected from the group consisting of D, E, R, K and H (SEQ ID NOS: 406-407), or

position 9 of said subsequence is not an amino acid selected from the group consisting of R, K and H (SEQ ID NOS: 408-409).

159. (Amended) The method of claim 158, wherein

position 1 of said subsequence is selected from the group consisting of A, Y, F and W (SEQ ID NOS: 410-423), or

position 3 of said subsequence is selected from the group consisting of L, V, I and M (SEQ ID NOS: 424-435), or

position 4 of said subsequence is G (SEQ ID NOS: 436-447), or

position 8 of said subsequence is selected from the group consisting of Y, F, W, L, V, I and M (SEQ ID NOS: 448-459).

160. (Amended) An isolated peptide of less than 15 amino acids and which comprises an HLA-A2.1 binding motif of 9-10 amino acids in length;

wherein said binding motif has a first amino acid anchor at position 2 of said motif which is I, and a second amino acid anchor at the C-terminus of said motif which is V, I, A or M (SEQ ID NOS: 460-461); or

wherein said binding motif has a first amino acid anchor at position 2 of said motif which is V, and a second amino acid anchor at the C-terminus of said motif which is L, V, I or M (SEQ ID NOS: 462-463); or

wherein said binding motif has a first amino acid anchor at position 2 of said motif which is A, and a second amino acid anchor at the C-terminus of said motif which is L, V or M (SEQ ID NOS: 464-465); or

*1/3  
concl*  
wherein said binding motif has a first amino acid anchor at position 2 of said motif which is T, and a second amino acid anchor at the C-terminus of said motif which is L, I or M (SEQ ID NOS: 466-467); or

wherein said binding motif has a first amino acid anchor at position 2 of said motif which is L, and a second amino acid anchor at the C-terminus of said motif which is M (SEQ ID NOS: 468-469); or

wherein said binding motif has a first amino acid anchor at position 2 of said motif which is M, and a second amino acid anchor at the C-terminus of said motif which is A or M (SEQ ID NOS: 470-471); and

wherein a peptide that consists of said binding motif elicits a CTL response when complexed with said HLA-A2.1 molecule.

161. (Amended) An isolated peptide of claim 160, wherein said peptide has the sequence KVAELVHFL (SEQ ID NO: 472).